Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses 177Lu vipivotide tetraxetan (Pluvicto), solution for injection, 1 GBq/mL (27 mCi/mL) at calibration.
 Indication: The treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least 1 androgen receptor pathway inhibitor and taxane-based chemotherapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
